Company Analysis MoonLake Immunotherapeutics
1. Summary
Advantages
- Price (13.83 $) is less than fair price (74.75 $)
Disadvantages
- Dividends (0%) are below the sector average (0.53%).
- The stock's return over the last year (-59.29%) is lower than the sector average (-2.93%).
- Current debt level 0.59% has increased over 5 years from 0.0497%.
- The company's current efficiency (ROE=-25.61%) is lower than the sector average (ROE=106.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| MoonLake Immunotherapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.5% | -14.5% | 0.4% |
| 90 days | 46.2% | -5.6% | 4.9% |
| 1 year | -59.3% | -2.9% | 20.9% |
MLTX vs Sector: MoonLake Immunotherapeutics has significantly underperformed the "Healthcare" sector by -56.35% over the past year.
MLTX vs Market: MoonLake Immunotherapeutics has significantly underperformed the market by -80.19% over the past year.
Stable price: MLTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MLTX with weekly volatility of -1.14% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (13.83 $) is lower than the fair price (74.75 $).
Price significantly below the fair price: The current price (13.83 $) is 440.5% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-28.99) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (-28.99) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (7.51) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (7.51) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-26.99) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-26.99) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 511.32% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (511.32%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-25.61%) is lower than that of the sector as a whole (106.63%).
ROE vs Market: The company's ROE (-25.61%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-24.03%) is lower than that of the sector as a whole (-2.32%).
ROA vs Market: The company's ROA (-24.03%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.83%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
